MARKET WIRECNBC • 1h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why PHVS Stock surged +2.32% Today — RQD Quant Desk Flash
$33.58 +2.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Pharvaris N.V. (PHVS) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $2.34B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHVS)Realized 20D OHLCV Swing Band: ±9.1%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PHVS Stock surged +2.32% Today — RQD Quant Desk Flash
Pharvaris N.V. (PHVS) surged +2.32% to $33.58, trading at 57% of its 52-week range ($21.02 – $43.25). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 57% of its 52-week range ($21.02 – $43.25) with RSI-14 at 59.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.1% around $33.58 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $65.5M annual free cash flow.
Live PHVS Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 3h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 6h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 6h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PHVS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PHVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.29%📐 HORIZONTAL RANGE
2026-10-30O $33.48H $33.94L $33.05C $33.58VOL 1.48M
RES: $47.96SUP: $26.96SMA50: $33.66SMA200: $31.00
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PHVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PHVS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PHVS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PHVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHVS)
Health Care Rank #157 of 1016
⚔️ RCUS vs PHVS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PHVS vs. RCUS, PBH, HCM, PGEN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pharvaris N.V. (PHVS) ranks #157 by composite RQD confidence (63/100, grade C) and #232 by equity capitalization ($2.34B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PHVS at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PHVS
ACTIVE
Pharvaris N.V. | C | 63/100 | — | — | — | +2.32% | $2.34B | Benchmark Subject |
| RCUS Arcus Biosciences Inc. | D- | 35/100 | — | — | -35.0% | +1.20% | $2.37B | /rcus-vs-phvs → |
| PBH Prestige Consumer Healthcare Inc. | B | 72/100 | 12.1x | 54.7% | 13.8% | +2.01% | $2.31B | /pbh-vs-phvs → |
| HCM HUTCHMED (China) Limited | D | 46/100 | 5.2x | — | -2.5% | +2.03% | $2.37B | /hcm-vs-phvs → |
| PGEN Precigen Inc. | D- | 35/100 | — | — | -35.0% | +9.21% | $2.38B | /pgen-vs-phvs → |
2. PHVS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTPharvaris N.V. (PHVS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.34B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. PHVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PHVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Pharvaris N.V. (NASDAQ: PHVS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $33.58 (+2.32% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHVS ranks #157 in composite RQD confidence.
How does PHVS compare to RCUS and PBH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHVS carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RCUS (Arcus Biosciences Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.37B) and PBH (Prestige Consumer Healthcare Inc.) posts a B grade (72/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.31B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PHVS?
For Pharvaris N.V. (PHVS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #157 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PHVS trading relative to its 50-day, 200-day, and 52-week technical levels?
PHVS last traded at $33.58 (+2.32% on volume of 879,103 shares), positioning the stock -0.24% below its 50-day simple moving average ($33.66) and +8.32% above its 200-day simple moving average ($31.00). Across its 52-week range of $21.02 to $43.25, PHVS sits at the 56.5% percentile with a 14-day RSI of 59.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.1% ($30.52 to $36.64).
PHVS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PHVS stock moving today?
Why PHVS Stock surged +2.32% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.